DE50202178D1 - NEW SULPHONATE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES - Google Patents

NEW SULPHONATE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES

Info

Publication number
DE50202178D1
DE50202178D1 DE50202178T DE50202178T DE50202178D1 DE 50202178 D1 DE50202178 D1 DE 50202178D1 DE 50202178 T DE50202178 T DE 50202178T DE 50202178 T DE50202178 T DE 50202178T DE 50202178 D1 DE50202178 D1 DE 50202178D1
Authority
DE
Germany
Prior art keywords
sulphonate
new
pyrazolopyridine derivatives
substituted pyrazolopyridine
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE50202178T
Other languages
German (de)
Inventor
Johannes-Peter Stasch
Achim Feurer
Stefan Weigand
Elke Stahl
Dietmar Flubacher
Cristina Alonso-Alija
Frank Wunder
Dieter Lang
Klaus Dembowsky
Alexander Straub
Elisabeth Perzborn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Priority to DE50202178T priority Critical patent/DE50202178D1/en
Application granted granted Critical
Publication of DE50202178D1 publication Critical patent/DE50202178D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE50202178T 2001-05-11 2002-04-30 NEW SULPHONATE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES Expired - Lifetime DE50202178D1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE50202178T DE50202178D1 (en) 2001-05-11 2002-04-30 NEW SULPHONATE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10122894A DE10122894A1 (en) 2001-05-11 2001-05-11 New pyrazolo(3,4-b)pyridin-3-yl)-5-pyrimidinyl sulfonates, are soluble guanyl cyclase stimulants useful e.g. for treating cardiovascular, thromboembolic or central nervous system diseases
DE50202178T DE50202178D1 (en) 2001-05-11 2002-04-30 NEW SULPHONATE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES
PCT/EP2002/004733 WO2002092596A1 (en) 2001-05-11 2002-04-30 Novel sulfonate substituted pyrazol pyridine dervivatives

Publications (1)

Publication Number Publication Date
DE50202178D1 true DE50202178D1 (en) 2005-03-10

Family

ID=7684395

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10122894A Withdrawn DE10122894A1 (en) 2001-05-11 2001-05-11 New pyrazolo(3,4-b)pyridin-3-yl)-5-pyrimidinyl sulfonates, are soluble guanyl cyclase stimulants useful e.g. for treating cardiovascular, thromboembolic or central nervous system diseases
DE50202178T Expired - Lifetime DE50202178D1 (en) 2001-05-11 2002-04-30 NEW SULPHONATE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE10122894A Withdrawn DE10122894A1 (en) 2001-05-11 2001-05-11 New pyrazolo(3,4-b)pyridin-3-yl)-5-pyrimidinyl sulfonates, are soluble guanyl cyclase stimulants useful e.g. for treating cardiovascular, thromboembolic or central nervous system diseases

Country Status (7)

Country Link
US (2) US6919345B2 (en)
EP (1) EP1390365B1 (en)
JP (2) JP2004529185A (en)
CA (1) CA2446812C (en)
DE (2) DE10122894A1 (en)
ES (1) ES2236534T3 (en)
WO (1) WO2002092596A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10122894A1 (en) * 2001-05-11 2002-11-14 Bayer Ag New pyrazolo(3,4-b)pyridin-3-yl)-5-pyrimidinyl sulfonates, are soluble guanyl cyclase stimulants useful e.g. for treating cardiovascular, thromboembolic or central nervous system diseases
DE10220570A1 (en) 2002-05-08 2003-11-20 Bayer Ag Carbamate-substituted pyrazolopyridines
DE102006043443A1 (en) 2006-09-15 2008-03-27 Bayer Healthcare Ag Novel aza-bicyclic compounds and their use
DE102006054757A1 (en) * 2006-11-21 2008-05-29 Bayer Healthcare Ag Novel aza-bicyclic compounds and their use
DE102007026392A1 (en) * 2007-06-06 2008-12-11 Bayer Healthcare Ag Solutions for the perfusion and preservation of organs and tissues
BRPI0817483A2 (en) 2007-10-05 2016-07-26 Sanofi Aventis Deutschland use of sulfonyl substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain
CA2743864A1 (en) 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102008063992A1 (en) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. New aliphatic substituted pyrazolopyridines and their use
DE102009004245A1 (en) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Novel fused, heteroatom-bridged pyrazole and imidazole derivatives and their use
UY33041A (en) * 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft PROCEDURE FOR THE PREPARATION OF {4,6-DIAMINO-2- [1- (2-FLUOROBENCIL) -1H-PIRAZOLO [3,4-B] PIRIDIN-3-IL] PIRIMIDIN-5-IL} CARBAMATO DE METTILO AND ITS PURIFICATION FOR USE AS A PHARMACEUTICAL ACTIVE PRINCIPLE
EP3415515B1 (en) * 2009-11-27 2019-12-25 Adverio Pharma GmbH Method for the preparation of methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate
WO2011119518A1 (en) 2010-03-25 2011-09-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010021637A1 (en) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituted 5-fluoro-1H-pyrazolopyridines and their use
EA023254B1 (en) 2010-05-27 2016-05-31 Мерк Шарп Энд Домэ Корп. Soluble guanylate cyclase activators
DE102010043380A1 (en) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituted carbamates and their use
DE102010043379A1 (en) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituted 6-fluoro-1H-pyrazolo [4,3-b] pyridines and their use
EA031602B1 (en) 2011-11-25 2019-01-31 Адверио Фарма Гмбх Processes for preraring aldehydes
AU2014220801A1 (en) 2013-02-21 2015-09-10 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
CA2984983A1 (en) 2015-05-06 2016-11-10 Bayer Pharma Aktiengesellschaft The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
LT3325013T (en) 2015-07-23 2020-11-10 Bayer Pharma Aktiengesellschaft Stimulators / activators of soluble guanylat cyclase in combination with a nep-inhibitor and/or an angiotensin aii-antagonist and the use thereof
AU2016371762A1 (en) 2015-12-14 2018-06-21 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of gastrointestinal sphincter dysfunction
CA3039735A1 (en) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Combination containing sgc activators and mineralocorticoid receptor antagonists
CN110022871A (en) 2016-10-11 2019-07-16 拜耳制药股份公司 Combination product comprising sGC stimulant and mineralocorticoid receptor antagonists
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
WO2018188590A1 (en) 2017-04-11 2018-10-18 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
SG11202011018PA (en) 2018-05-15 2020-12-30 Bayer Ag 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
MX2021000363A (en) 2018-07-11 2021-04-29 Cyclerion Therapeutics Inc USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS.
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19642255A1 (en) 1996-10-14 1998-04-16 Bayer Ag Use of 1-benzyl-3- (substituted-hetaryl) fused pyrazole derivatives
CZ130999A3 (en) 1996-10-14 1999-07-14 Bayer Aktiengesellschaft Heterocyclylmethyl substituted derivatives of pyrazole, process of their preparation, pharmaceutical compositions containing thereof and their use for preparing medicaments
DE19649460A1 (en) 1996-11-26 1998-05-28 Bayer Ag New substituted pyrazole derivatives
US6451805B1 (en) * 1997-11-14 2002-09-17 Bayer Aktiengesellschaft Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
DE19834045A1 (en) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl) -1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b] pyridine
DE19834044A1 (en) * 1998-07-29 2000-02-03 Bayer Ag New substituted pyrazole derivatives
DE19834047A1 (en) 1998-07-29 2000-02-03 Bayer Ag Substituted pyrazole derivatives
DE19846514A1 (en) 1998-10-09 2000-04-20 Bayer Ag New arylmethyl and heterocyclylmethyl substituted heteroaryl-indazole derivatives useful in treatment of cardiovascular, ischemic and urogenital disorders
DE19920352A1 (en) * 1999-05-04 2000-11-09 Bayer Ag Substituted pyrazole derivative
DE19942809A1 (en) * 1999-09-08 2001-03-15 Bayer Ag Process for the preparation of substituted pyrimidine derivatives
DE10057751A1 (en) 2000-11-22 2002-05-23 Bayer Ag New carbamate-substituted pyrazolo (3,4-b) pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation
DE10122894A1 (en) * 2001-05-11 2002-11-14 Bayer Ag New pyrazolo(3,4-b)pyridin-3-yl)-5-pyrimidinyl sulfonates, are soluble guanyl cyclase stimulants useful e.g. for treating cardiovascular, thromboembolic or central nervous system diseases

Also Published As

Publication number Publication date
WO2002092596A1 (en) 2002-11-21
EP1390365B1 (en) 2005-02-02
US20040171832A1 (en) 2004-09-02
CA2446812A1 (en) 2002-11-21
JP2009292826A (en) 2009-12-17
DE10122894A1 (en) 2002-11-14
EP1390365A1 (en) 2004-02-25
ES2236534T3 (en) 2005-07-16
JP2004529185A (en) 2004-09-24
US6919345B2 (en) 2005-07-19
US7317016B2 (en) 2008-01-08
US20050245553A1 (en) 2005-11-03
CA2446812C (en) 2011-02-01

Similar Documents

Publication Publication Date Title
DE50105334D1 (en) NEW CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES
DE50202178D1 (en) NEW SULPHONATE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES
ATE298752T1 (en) NEW PYRIDINE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES
ATE271031T1 (en) NEW PHENYLPROPARGYLETHER DERIVATIVES
DE60328671D1 (en) NEW AMINOBENZAMID DERIVATIVES
EE200300273A (en) Substituted imidazopyridines
NO20035476D0 (en) azaindoles
ATE319451T1 (en) TETRAHYDROCINOLINE DERIVATIVES
DE50111292D1 (en) NEW SULFONAMIDE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES
ATE312827T1 (en) 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES
NO20042755L (en) Amide-substituted imidazopyridines
EE200300447A (en) Substituted benzofuran-2-carboxamides derivatives
DE60223031D1 (en) ARYLPIPERAZINE-BOUND TETRAHYDROINDOLON DERIVATIVES
DE60111268D1 (en) NEW PULLEOMUTILINE DERIVATIVES
DE60103033D1 (en) NEW PHENYLHETEROALKYLAMINE DERIVATIVES
DE60334907D1 (en) NEW PHTHALAMID DERIVATIVES
DE60203534D1 (en) NEW PHENYL-PROPARGYL ETHER DERIVATIVES
ATE382601T1 (en) SUBSTITUTED 4-AMINOCYCLOHEXANOLE DERIVATIVES
DE60126125D1 (en) NEW CARBAPENEM DERIVATIVES
DE60217710D1 (en) NEW FORMULATION
DE50309081D1 (en) NEW DIKETOPYRROLOPYROLPIGMENTS
DE60202381D1 (en) PAROXETINE-N-FORMYL DERIVATIVES
DE60206043D1 (en) NEW INDOOR DERIVATIVES
DE60211574D1 (en) Merge unit
DE50106655D1 (en) NEW PYRIDINE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 1335, DE